Endotoxin Testing for Plasma-Derived Biologics: Managing Protein Matrix Interference and Ensuring Reliable Results

Introduction: Why Endotoxin Testing Matters for Plasma-Derived Biologics

Plasma-derived biologics play an important role in modern medicine. Human serum albumin, immunoglobulin preparations, coagulation factors, and other plasma-derived therapeutic products are used in clinical settings where product quality and patient safety are critical.

Because many of these products are administered parenterally, manufacturers must establish appropriate controls for bacterial endotoxin contamination as part of their broader quality and safety programs. Endotoxin contamination can originate from water, process equipment, raw materials, containers, or other manufacturing-related sources. Even when manufacturing processes include multiple purification and filtration stages, these steps should not be assumed to eliminate the need for appropriate endotoxin controls.

Testing plasma-derived products presents a challenge beyond simply detecting endotoxin. These products often contain concentrated proteins, stabilizers, salts, and other formulation components that may affect analytical performance. A method that performs well with a simple aqueous sample may behave differently when applied to a protein-rich biological matrix.

For quality control laboratories, the key question is therefore not just whether an assay produces a result, but whether the selected method can reliably measure endotoxin in the specific product under the intended testing conditions.

This guide explores the principal challenges of endotoxin testing for plasma-derived biologics, from matrix interference and method suitability to dilution strategy, positive product control recovery, and ongoing quality oversight.

1. Understanding the Endotoxin Risk in Plasma-Derived Products

Bacterial endotoxins are lipopolysaccharide (LPS) components associated with the outer membrane of Gram-negative bacteria. They can enter pharmaceutical manufacturing processes through contaminated water, materials, equipment, or other sources.

For plasma-derived biologics, endotoxin control should be considered within the context of the entire manufacturing process rather than only at the finished-product stage.

1.1 Albumin products

Human serum albumin is used in a range of clinical applications, including volume replacement and other settings specified by the approved product labeling. Depending on the formulation and manufacturing process, albumin products may contain high protein concentrations and formulation excipients that influence assay behavior.

Protein-rich matrices can affect sample handling and analytical measurements. For example, changes in pH, ionic strength, or protein concentration may alter the conditions under which an endotoxin assay operates.

Consequently, an assay procedure established for one albumin formulation should not automatically be transferred to another formulation without appropriate evaluation.

1.2 Immunoglobulin preparations

Intravenous and subcutaneous immunoglobulin products can differ in concentration, stabilizer composition, pH, and other formulation characteristics.

These differences matter when establishing a suitable endotoxin testing procedure. A formulation containing one stabilizer may behave differently from a formulation containing another, even when both products contain the same principal therapeutic protein.

The laboratory should therefore evaluate the actual product matrix and intended testing conditions rather than relying exclusively on experience with another immunoglobulin product.

1.3 Coagulation factors and other plasma-derived proteins

Coagulation factors and other specialized plasma-derived products may contain additional formulation components and may require product-specific analytical procedures.

Their endotoxin testing strategies should account for the product's intended use, applicable quality requirements, and the characteristics of the formulation.

The practical principle is straightforward: plasma-derived products should be evaluated individually for assay suitability when their composition, concentration, or intended testing conditions could affect analytical performance.

2. How Protein-Rich Matrices Can Affect Endotoxin Assays

Matrix interference occurs when components of a sample influence the analytical response independently of the endotoxin concentration being measured.

In endotoxin testing, interference can produce artificially low results, artificially high results, or inconsistent measurements. The direction and magnitude of the effect depend on the sample matrix, reagent system, assay format, and testing conditions.

2.1 Inhibition: When endotoxin recovery is too low

Inhibition occurs when the sample reduces or suppresses the expected response of the endotoxin detection system.

Potential contributing factors include:

• Sample pH outside the assay's suitable operating range.

• High concentrations of proteins or formulation excipients.

• Ionic conditions that affect the assay reaction.

• Components that interact with endotoxin and change its availability to the detection system.

• Sample preparation or handling conditions that alter assay performance.

A low endotoxin result does not necessarily demonstrate that the product contains little endotoxin. If inhibition is present, the measured response may underestimate the amount that the method should detect.

This is particularly important when a result is close to a product-specific acceptance criterion. A false-low result can create unwarranted confidence in product quality.

2.2 Enhancement: When the analytical response is too high

Enhancement occurs when a sample produces a greater response than expected under the established assay conditions.

Potential causes include matrix-related effects, contamination introduced during preparation, and analytical variability.

An enhanced result may lead to unnecessary investigations or delays if the laboratory assumes that every elevated measurement reflects genuine contamination.

However, enhancement should never be dismissed simply because a sample appears difficult to test. The laboratory must investigate the cause and establish whether the method remains suitable.

2.3 Why interference must be evaluated experimentally

The appearance of a product, its protein concentration, or its manufacturing history cannot independently establish whether an endotoxin assay is suitable.

Likewise, successful testing of a similar formulation does not automatically demonstrate suitability for a different product.

Method suitability studies provide experimental evidence that the assay can perform acceptably in the presence of the actual sample matrix. They are essential for distinguishing genuine endotoxin measurements from matrix-related analytical effects.

3. Selecting an Appropriate Endotoxin Testing Method

The appropriate method depends on the product, the applicable compendial or regulatory requirements, the laboratory's validated procedure, and the intended use of the result.

Common bacterial endotoxins testing approaches include gel-clot methods and photometric methods, such as kinetic chromogenic and kinetic turbidimetric assays. Recombinant reagent methods may also be appropriate when their use is supported by the relevant requirements and product-specific method suitability evidence.

3.1 Gel-clot endotoxin testing

Gel-clot testing is based on the formation of a gel in response to endotoxin under specified assay conditions.

Its advantages include a relatively straightforward visual endpoint and limited dependence on optical measurement systems. However, the method provides an endpoint-based result rather than a continuous quantitative measurement.

For laboratories evaluating a gel-clot approach, the key considerations include reagent sensitivity, sample dilution, reaction conditions, controls, and the ability to interpret the endpoint reliably.

FireGene's gel-clot endotoxin test kit can be considered as one option when evaluating an appropriate TAL-based testing workflow. Actual suitability must be established for the specific product and procedure.

3.2 Kinetic chromogenic endotoxin testing

Kinetic chromogenic assays measure a color-producing reaction over time. The rate of color development is related to endotoxin concentration within the method's established analytical range.

The quantitative format can be useful when laboratories need to monitor trends, compare results across batches, or investigate changes in process performance.

For plasma-derived products, however, optical and matrix-related effects require particular attention. Sample color, turbidity, dilution, and other formulation characteristics may affect the observed response, depending on the assay design.

A suitable calibration system and acceptable control performance are essential. A visually clear sample is not, by itself, evidence that the matrix cannot interfere.

FireGene offers a kinetic chromogenic endotoxin test kit for laboratories evaluating quantitative TAL-based endotoxin testing workflows.

3.3 Recombinant reagent methods

Recombinant endotoxin detection reagents provide an alternative to animal-derived lysate reagents. Their use has received increasing attention as laboratories evaluate analytical approaches that reduce reliance on animal-derived materials.

The FDA's March 2026 Pyrogen and Endotoxins Testing: Questions and Answers, Edition 2, discusses the broader scope of recombinant reagents and emphasizes verifying that the selected assay is suitable for its intended purpose.

A laboratory considering a recombinant method should review the applicable requirements, the supplier's technical documentation, and the experiments needed to demonstrate product-specific suitability.

Method selection should be driven by evidence, not by the assumption that one assay format is universally superior.

4. Method Suitability Testing: Establishing Confidence in the Results

Method suitability testing evaluates whether the chosen endotoxin assay can perform acceptably in the presence of the sample matrix.

For plasma-derived products, this evaluation should be designed around the actual product formulation and the intended analytical procedure.

4.1 Evaluate positive product control recovery

A positive product control (PPC) is prepared by adding a known quantity of endotoxin to the product sample under the prescribed test conditions.

The measured response is compared with the expected response to determine whether the matrix affects endotoxin detection.

For methods governed by USP General Chapter <85>, the applicable PPC recovery criteria and procedure should be followed. A commonly applied recovery range is 50%–200%, subject to the governing method and applicable requirements.

Poor recovery may indicate inhibition, while recovery above the accepted range may indicate enhancement or another analytical issue.

PPC recovery should be assessed at the relevant product dilution and under the conditions used for the actual test. A satisfactory result obtained in a different matrix or under different conditions does not necessarily establish suitability for the current procedure.

4.2 Evaluate the actual testing conditions

A method suitability assessment should document the key factors that may affect the result, including:

• Product identity and formulation.

• Sample dilution and preparation procedure.

• Reagent system and reagent sensitivity.

• pH and other relevant reaction conditions.

• Positive and negative control performance.

• PPC recovery and applicable acceptance criteria.

• Relevant observations, deviations, and conclusions.

The precise study design should reflect the complexity of the product and the applicable procedure.

4.3 Reassess suitability when the product changes

A previously suitable method may require reassessment following a meaningful change in product formulation, manufacturing process, concentration, or sample preparation procedure.

Changes to stabilizers, excipients, or other components can alter the matrix and potentially affect assay performance.

A documented change-control process helps determine whether existing evidence remains adequate or additional suitability experiments are warranted.

5. Optimizing Sample Dilution Without Losing Sensitivity

Dilution is one of the most common tools used to reduce matrix interference in endotoxin testing.

By reducing the concentration of interfering components, dilution may improve assay performance. However, it also reduces the endotoxin concentration presented to the detection system.

The objective is to identify a dilution that sufficiently reduces interference while preserving the ability to detect endotoxin at the required level.

5.1 Understand the maximum valid dilution

The maximum valid dilution (MVD) defines the maximum dilution permitted under the applicable bacterial endotoxins testing framework for a particular product and endotoxin limit.

Under the conventional USP <85> framework, MVD is calculated using the endotoxin limit, sample concentration, and assay sensitivity. The exact calculation depends on how the product limit and concentration are expressed.

A simplified form is:

MVD = Endotoxin limit × Sample concentration / Assay sensitivity

The units must be consistent, and the calculation must follow the applicable compendial procedure.

The MVD is not a recommendation to dilute every sample to the maximum. It establishes an upper boundary for the dilution strategy under the relevant assumptions.

5.2 Avoid excessive dilution

Excessive dilution may reduce interference but can also reduce endotoxin below the method's detection capability.

This creates a critical distinction: an assay may produce a negative result because endotoxin is absent or sufficiently low, or because the sample was diluted beyond a level at which the method could reliably detect it.

Therefore, the selected dilution should be supported by method suitability data and should remain within the applicable MVD.

5.3 Use dilution studies to investigate interference

When interference is suspected, a structured dilution study can help identify conditions under which acceptable PPC recovery is achieved.

The laboratory should evaluate the resulting data in relation to the product-specific endotoxin limit, assay sensitivity, and required detection capability.

Dilution should not be used as a substitute for investigating unexplained analytical behavior. If suitable recovery cannot be demonstrated within the valid testing range, further investigation or an alternative validated procedure may be necessary.

6. Sample Preparation and Contamination Prevention

Reliable endotoxin testing depends on more than the detection reagent. Sample preparation, water quality, consumables, and laboratory technique can all influence the final result.

6.1 Use suitable endotoxin-controlled water

Water used for assay preparation and dilution should meet the applicable requirements for bacterial endotoxins testing.

Water that is microbiologically acceptable is not necessarily suitable for endotoxin testing, because bacterial endotoxins can remain even when viable microorganisms are no longer present.

FireGene provides endotoxin assay water intended for endotoxin testing workflows. Laboratories should verify the product specifications and use it according to the assay procedure.

6.2 Select appropriate consumables

Pipette tips, tubes, plates, and other consumables that contact the sample or reagents should be suitable for endotoxin testing.

Contaminated consumables can introduce endotoxin into a sample and produce misleading results. The use of appropriate consumables, controlled handling, and qualified suppliers helps reduce this risk.

6.3 Standardize handling procedures

Inconsistent handling can introduce variability between analysts, runs, or laboratories.

Standard operating procedures should define the applicable sample preparation steps, dilution sequence, mixing technique, timing, storage conditions, and controls.

Where the product is particularly sensitive to handling conditions, these factors should be evaluated during method development or suitability assessment.

6.4 Review sample storage and hold time

The laboratory should establish appropriate sample storage and hold-time conditions based on the product's characteristics and available evidence.

Changes in the sample during storage may affect endotoxin recovery or assay performance. A sample that produces acceptable results immediately after preparation may not necessarily behave identically after prolonged storage.

Where relevant, studies should assess whether the established storage and hold-time conditions preserve the suitability of the test procedure.

7. Quality Control Beyond the Finished Product

Finished-product testing is only one component of an effective endotoxin control strategy.

For plasma-derived biologics, manufacturers should consider endotoxin risks throughout the manufacturing process and establish controls appropriate to the materials, operations, and product.

7.1 Water and process materials

Water systems, process solutions, raw materials, and product-contact equipment can be potential sources of endotoxin contamination.

Monitoring strategies should be based on process knowledge, risk assessment, and the applicable quality requirements.

A sudden increase in endotoxin results may indicate a localized problem or a broader process change. Reviewing results across relevant process stages can help identify the likely source.

7.2 Trend analysis

Routine testing generates data that can be used to identify changes before they become recurring quality problems.

Laboratories should evaluate relevant trends, such as:

• Increasing endotoxin levels in process samples.

• Repeated PPC recovery failures.

• Greater variability between replicate measurements.

• Changes associated with a new reagent lot.

• Differences between analysts or testing instruments.

• Recurring deviations linked to sample preparation.

Trend analysis should complement established specifications and investigation procedures rather than replace them.

7.3 Reagent and method control

Changes in reagent lots, instruments, operators, and analytical procedures may affect assay performance.

Laboratories should follow their established procedures for reagent qualification, instrument maintenance, calibration where applicable, analyst training, and documentation.

Where a new reagent lot or method change may affect the result, the laboratory should determine what verification is needed under its quality system.

FireGene's control standard endotoxin is one product category that may support applicable endotoxin assay control workflows. Its use should follow the relevant assay instructions and laboratory procedures.

8. Common Problems in Plasma-Derived Biologics Endotoxin Testing

Understanding recurring analytical problems can help laboratories investigate failures more efficiently.

Problem 1: PPC recovery falls below the acceptance range

Possible causes: Matrix inhibition, unsuitable pH, inadequate dilution, or a problem with reagents or assay execution.

Recommended response: Review the sample preparation procedure, verify reagent and control performance, and evaluate whether a different dilution within the permitted range improves recovery.

Do not report a result as reliable merely because the unspiked sample gives a numerical reading.

Problem 2: PPC recovery exceeds the acceptance range

Possible causes: Matrix enhancement, contamination introduced during preparation, or analytical variability.

Recommended response: Review contamination controls, compare appropriate controls, assess replicate behavior, and investigate the source of the enhanced response.

The investigation should establish whether the observed effect is attributable to the matrix or another aspect of the procedure.

Problem 3: Results vary substantially between runs

Possible causes: Inconsistent sample handling, differences in reagent or consumable lots, timing variation, instrument-related factors, or unstable sample conditions.

Recommended response: Review run records and control data, identify potential changes, and determine whether the variability is linked to a specific factor.

A structured investigation is generally more informative than repeatedly testing the same sample without changing or evaluating the relevant conditions.

Problem 4: A negative result is obtained after extensive dilution

Possible cause: Endotoxin may have been diluted below the assay's detection capability.

Recommended response: Verify the MVD calculation and ensure that the selected dilution preserves the required detection capability. Demonstrate method suitability under the actual testing conditions.

A negative result is meaningful only when the method is suitable and the result is interpretable within the established analytical limits.

Problem 5: A method suitable for one product fails with another

Possible cause: Differences in protein concentration, excipients, pH, or other formulation characteristics.

Recommended response: Treat the new product as a distinct matrix for suitability purposes. Evaluate the actual formulation and document the evidence supporting the selected procedure.

9. Regulatory Considerations and Documentation

Endotoxin testing for plasma-derived biologics should be conducted in accordance with the requirements applicable to the product, jurisdiction, and approved quality system.

Relevant references may include USP General Chapter <85>, applicable product monographs, and current FDA guidance. Where recombinant reagents are considered, USP General Chapter <86> and the applicable regulatory expectations should also be reviewed.

The FDA's March 2026 Pyrogen and Endotoxins Testing: Questions and Answers, Edition 2, provides updated recommendations concerning bacterial endotoxins testing and the use of recombinant reagents. The FDA also emphasizes the need to verify method suitability for the intended material and purpose.

Read the current FDA guidance on pyrogen and endotoxins testing when developing or updating an endotoxin testing strategy.

Documentation should provide a clear record of:

• The selected method and rationale.

• Applicable endotoxin limits and acceptance criteria.

• Reagent and control information.

• Sample preparation and dilution calculations.

• Method suitability studies and PPC recovery.

• Deviations, investigations, and corrective actions.

• Relevant changes to the product or analytical procedure.

The endotoxin limit must be established for the specific product using the applicable requirements. A limit used for one biological product should not automatically be applied to another product simply because both are plasma-derived.

10. A Practical Checklist for Quality Control Laboratories

Before implementing or revising an endotoxin testing procedure for a plasma-derived biologic, consider the following checklist.

Product understanding

• Confirm the product formulation and relevant matrix characteristics.

• Identify potential contamination sources and relevant process controls.

• Establish the applicable endotoxin limit and testing requirements.

Method suitability

• Select a method appropriate for the product and intended purpose.

• Verify reagent performance and required controls.

• Demonstrate acceptable PPC recovery under the intended test conditions.

• Investigate inhibition or enhancement before relying on the results.

Sample preparation

• Use suitable endotoxin-controlled water and consumables.

• Standardize sample preparation and handling.

• Establish a justified dilution strategy within the applicable MVD.

• Confirm that storage and hold-time conditions are appropriate.

Ongoing quality assurance

• Monitor relevant control results and analytical trends.

• Investigate recurring deviations and unexplained variability.

• Reassess suitability when meaningful product or method changes occur.

• Maintain complete and traceable documentation.

This approach supports a more reliable and defensible endotoxin testing program while helping laboratories identify problems before they affect routine testing.

Conclusion: Reliable Results Begin With Product-Specific Method Suitability

Endotoxin testing for plasma-derived biologics requires careful attention to the relationship between the product matrix and the selected analytical method.

High protein concentrations, formulation excipients, sample handling, and dilution can all influence assay performance. For this reason, laboratories should not rely solely on a method's general performance characteristics or on its successful use with another product.

A robust strategy combines appropriate method selection, product-specific suitability studies, acceptable PPC recovery, justified dilution, contamination control, and ongoing review of analytical data.

For manufacturers of albumin, immunoglobulins, coagulation factors, and other plasma-derived products, these practices help strengthen confidence in endotoxin results and support consistent quality control.

FireGene offers endotoxin testing reagents and supporting products for laboratories developing and maintaining appropriate testing workflows. Explore the FireGene endotoxin assay reagent collection to learn more about available solutions.

Important note: This article is intended for scientific and educational purposes. Product-specific endotoxin limits, testing procedures, acceptance criteria, and regulatory requirements should always be established according to the applicable compendial standards, approved specifications, and validated laboratory procedures.

References

1. U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers — Guidance for Industry, Edition 2. March 2026.

2. United States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test. Consult the current official edition.

3. United States Pharmacopeia. General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents. Consult the current official edition and applicable implementation requirements.